Amgen Inc.

Equities

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-02-21 pm EST 5-day change 1st Jan Change
283.5 USD -0.02% Intraday chart for Amgen Inc. -2.28% -1.58%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Chart Amgen Inc.
More charts
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.6% of net sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
283.5 USD
Average target price
303.6 USD
Spread / Average Target
+7.12%
Consensus
1st Jan change Capi.
-1.58% 152 B $
+27.96% 680 B $
+19.01% 546 B $
+1.24% 380 B $
+17.52% 323 B $
+13.02% 310 B $
-5.58% 212 B $
+6.09% 211 B $
-4.70% 200 B $
-3.89% 156 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Amgen Inc. - Nasdaq
  4. News Amgen Inc.
  5. Amgen's Rights to Bempikibart Regained by Q32 Bio
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer